Interferon antibodies may negate the antiviral effects of recombinant α‐interferon treatment in patients with chronic hepatitis B virus infection
Anna Suk‐Fong Lok, Ching‐Lung Lai, Elsie Kit‐Yee Leung – 1 December 1990 – In a randomized controlled trial of recombinant α‐2a interferon for chronic hepatitis B, interferon antibodies developed in 21 (39%) of 54 Chinese adults who received IFN. No correlation was observed between sex, age, pretreatment serum ALT level or liver histological findings and the development of interferon antibodies. Antibodies were significantly more likely to develop in patients who received lower doses (2.5 or 5 MU/m2) of α‐2a interferon than in those who received a higher dose (10 MU/m2): 53% vs.